Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.
Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.
Our experienced oncologists and clinical research staff carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study.
Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.
The National Cancer Institute has a brochure “Taking Part in Cancer Treatment Research Studies” to help you understand the details of clinical trials.
To learn more about our ongoing trials for cancer treatment and prevention, please contact Tina Bergner, RN, BSN, OCN, oncology clinical research coordinator, at 609-537-7042, or e-mail her at firstname.lastname@example.org for more information.
3D-PREDICT REGISTRY: 3D Prediction of patient-specific response using ex vivo interrogation of live cells from tumors
Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery
Molecular and biochemical characterization of malignant and metastatic brain tumors
Genomically-guided treatment trial in brain metastasis
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma With Elevated Mutational Burden
Testing the Use of the Immunotherapy Drugs, Ipilimumab and Nivolumab, Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Assessing quality of life in adult neuro-oncology patients after Cyberknife or WBRT (Whole Brain Radiation Therapy), a prospective registry
The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme
Registry to evaluate effectiveness and safety of the Nanoknife system for the ablation of stage 3 pancreatic cancer – DIRECT
Circulating Biomarkers and Cancer
A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer” with Protocol number M14-239
A randomized phase III trial of induction/consolidation Atezolizumab + SBRT Versus SBRT alone in high risk, early stage NSCLC
SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
A randomized trial of the altering intake, managing symptoms interventions for bowel dysfunction in rectal cancer survivors compared to a healthy living education control: A feasibility and preliminary efficacy study (AIMS-RC) S1820
Bespoke Study of ctDNA Guided Therapy in Colorectal Cancer
NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma
Cancer Tissue Biorepository
Diagnostic Markers in Patients with Bladder Cancer
Stereotactic Body Radiation Therapy or Intesity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer